1. Home
  2. UMBF vs JAZZ Comparison

UMBF vs JAZZ Comparison

Compare UMBF & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UMBF
  • JAZZ
  • Stock Information
  • Founded
  • UMBF 1913
  • JAZZ 2003
  • Country
  • UMBF United States
  • JAZZ Ireland
  • Employees
  • UMBF N/A
  • JAZZ N/A
  • Industry
  • UMBF Major Banks
  • JAZZ Biotechnology: Pharmaceutical Preparations
  • Sector
  • UMBF Finance
  • JAZZ Health Care
  • Exchange
  • UMBF Nasdaq
  • JAZZ Nasdaq
  • Market Cap
  • UMBF 8.0B
  • JAZZ 6.7B
  • IPO Year
  • UMBF N/A
  • JAZZ 2007
  • Fundamental
  • Price
  • UMBF $110.55
  • JAZZ $110.27
  • Analyst Decision
  • UMBF Buy
  • JAZZ Strong Buy
  • Analyst Count
  • UMBF 8
  • JAZZ 12
  • Target Price
  • UMBF $129.88
  • JAZZ $183.08
  • AVG Volume (30 Days)
  • UMBF 663.0K
  • JAZZ 651.1K
  • Earning Date
  • UMBF 07-29-2025
  • JAZZ 07-30-2025
  • Dividend Yield
  • UMBF 1.44%
  • JAZZ N/A
  • EPS Growth
  • UMBF 2.38
  • JAZZ 49.21
  • EPS
  • UMBF 7.71
  • JAZZ 7.51
  • Revenue
  • UMBF $1,657,118,000.00
  • JAZZ $4,064,808,000.00
  • Revenue This Year
  • UMBF $63.72
  • JAZZ $6.05
  • Revenue Next Year
  • UMBF $7.79
  • JAZZ $4.68
  • P/E Ratio
  • UMBF $14.39
  • JAZZ $14.72
  • Revenue Growth
  • UMBF 13.44
  • JAZZ 5.76
  • 52 Week Low
  • UMBF $82.00
  • JAZZ $95.49
  • 52 Week High
  • UMBF $129.94
  • JAZZ $148.06
  • Technical
  • Relative Strength Index (RSI)
  • UMBF 63.25
  • JAZZ 52.75
  • Support Level
  • UMBF $108.23
  • JAZZ $109.27
  • Resistance Level
  • UMBF $112.16
  • JAZZ $112.70
  • Average True Range (ATR)
  • UMBF 2.48
  • JAZZ 2.72
  • MACD
  • UMBF 0.60
  • JAZZ 0.42
  • Stochastic Oscillator
  • UMBF 87.67
  • JAZZ 67.81

About UMBF UMB Financial Corporation

UMB Financial Corp, or UMBF, is a financial services holding company offering a suite of banking services and asset servicing to its customers in the United States and around the world. Its client base includes commercial, institutional, and personal customers. Along with its subsidiaries, the company operates in the following business segments: Commercial Banking, Institutional Banking, and Personal Banking. A majority of its revenue is generated from the Commercial Banking segment, which serves the commercial banking and treasury management needs of small to middle-market businesses through various products and services such as commercial loans, commercial real estate financing, commercial credit cards, letters of credit, loan syndication services, consultative services, and others.

About JAZZ Jazz Pharmaceuticals plc (Ireland)

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Share on Social Networks: